Strategic Hiring Leverage recent executive appointments (CFO, CMO, VP Program Leader, CSO) to initiate conversations around governance, budgeting for trials, and program milestones that require partner engagement, CRO support, and resource planning.

Funding Momentum With substantial funding ($98M) and a notable Series A achieved, pursue partnerships that align with scaled development, commercial planning, or co-investment opportunities to accelerate clinical programs and share risk.

Clinical Focus Target opportunities in vision restoration therapies and photoreceptor protection where corporate interest overlaps with ophthalmology-based gene therapy platforms; propose collaboration on preclinical to early clinical milestones or delivery technology.

Strategic Acquisition History Acknowledge past Novartis Venture Fund activity and optogenetic tech lineage to approach large pharma and investors for potential licensing, co-development, or acquisition discussions centered on optogenetics and gene delivery innovations.

Global Market Readiness Position offerings around scalable manufacturing, regulatory strategy support, and market access planning to align with a lean, high-impact biotech with limited internal headcount but strong funding and leadership depth.